Loading...
•
Sep 30, 2020
Fate Therapeutics Q3 2020 Earnings Report
Fate Therapeutics reported third quarter 2020 financial results and highlighted operational progress.
Key Takeaways
Fate Therapeutics reported revenue of $7.6 million for the third quarter of 2020, derived from collaborations with Janssen and Ono Pharmaceutical. The company's cash, cash equivalents, and investments totaled $502.0 million as of September 30, 2020.
First patients treated with dual-antigen targeting regimen of FT596 in combination with Rituximab for B-cell Lymphoma.
FT596 Phase 1 Study Expanded to Include Chronic Lymphocytic Leukemia.
First Patient Treated with FT516 in Combination with Avelumab for Advanced Solid Tumors.
Enrollment Initiated with FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for Acute Myeloid Leukemia and Multiple Myeloma.
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Fate Therapeutics plans to initiate a multi-center Phase 1 clinical trial of FT819 in the fourth quarter of 2020.